• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

CVS to sell cheaper, generic version of Impax’s allergy injection

January 12, 2017 By Sarah Faulkner

CVS to sell cheaper, generic version of Impax's allergy injectionCVS Health Corp. (NYSE:CVS) said today that it will start selling a generic version of Impax Laboratories‘ (NSDQ:IPXL) emergency allergy injection, Adrenaclick. The device is similar to Mylan‘s (NSDQ:MYL) EpiPen, although regulators do not consider the 2 devices to be exactly the same.

The Adrenaclick has a list price of more than $400, but the generic is available at all CVS pharmacy locations for both insured and uninsured patients at a cash price of $109.99.

Impax’s device needs to be assembled by hand, unlike Mylan’s EpiPen. The EpiPen 2-pack has a list price of $649.99, according to Reuters, while Mylan’s newly-launched generic rings in at $339.99.

CVS’ move comes as drug pricing is at the forefront of healthcare policy discussion among lawmakers. Mylan came under fire last year after reports showed that the Canonsburg, Penn.-based company raised the price of its emergency allergy epinephrine injector by 500% since it acquired the product in 2007 from Merck.

Mylan and Teva Pharmaceuticals (NYSE:TEVA) have both been named in an ongoing federal investigation into generic drug pricing and 1 day after Mylan launched its 1st generic EpiPen, attorney generals from 20 states filed a civil complaint against Mylan, Teva and 4 other generic drug makers.

Pharmaceutical giants like Mylan have focused the blame for high drug prices on pharmacy benefits managers, such as CVS Caremark. CVS Pharmacy president Helena Foulkes reportedly said the company chose to make Impax’s generic device available after CVS pharmacists heard complaints and concerns from customers over EpiPen’s price increases.

Yesterday, in his 1st formal press conference since he won the presidential election in November, President-elect Donald Trump said that drug prices are too high. “They’re getting away with murder,” he said. “We’re the largest buyer of drugs in the world, and yet we don’t bid properly. We’re going to start bidding, and we’re going to save billions of dollars over a period of time.”

Filed Under: Drug-Device Combinations, Featured, Respiratory, Wall Street Beat Tagged With: CVS Health, Impax Laboratories, Mylan

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS